Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Jcar017 (Lisocabtagene Maraleucel) Indolent B-Cell Non-Hodgkin Lymphoma	Fred Hutchinson Cancer Center	P1/2	CCC (54)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells Burkitt Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (54)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells Plasmablastic Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (54)
LENVATINIB Adenocarcinoma of the Pancreas	Salubris Biotherapeutics Inc	P1/2	CCC (54)
LENVATINIB Non-Small Cell Squamous Lung Carcinoma	AbbVie	P1/2	CCC (54)
Linperlisib Extranodal Natural Killer/T Cell Lymphoma	Sun Yat-sen University	P1/2	CCC (54)
Ly-M003 Wilson Disease	Lingyi Biotech Co., Ltd.	P1/2	CCC (54)
Mesna T-Cell Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (54)
Mitoxantrone Acute Biphenotypic Leukemia	University of Washington	P1/2	CCC (54)
mln9708 Haematological Malignancy	CellCentric Ltd.	P1/2	CCC (54)
Nggt002 Phenylketonuria	NGGT INC.	P1/2	CCC (54)
Nivolumab Central Nervous System Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (54)
Oxodotreotide Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Oxodotreotide Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P1/2	CCC (54)
Pamiparib Glioblastoma	Nader Sanai	P1/2	CCC (54)
PEGFILGRASTIM Breast Carcinoma	Centre Georges Francois Leclerc	P1/2	CCC (54)
Pembrolizumab Basal Cell Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	CCC (54)
Pembrolizumab Endocervical Carcinoma	NGM Biopharmaceuticals, Inc	P1/2	CCC (54)
Pembrolizumab Malignant Glioma	Essen Biotech	P1/2	CCC (54)
Pembrolizumab Liver Metastases	VA Ann Arbor Healthcare System	P1/2	CCC (54)
Pembrolizumab Malignant Peripheral Nerve Sheath Tumor	Seattle Children's Hospital	P1/2	CCC (54)
Pembrolizumab Ureter Neoplasm	Eli Lilly and Company	P1/2	CCC (54)
Pioglitazone Hyperglycemia	Rambam Health Care Campus	P1/2	CCC (54)
PREDNISONE TABLETS Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Recombinant Human Il12/15-Pdl1B Oncolytic Hsv-1 ) Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)

Showing 351 to 375 of 8,400 assets

PreviousPage 15 of 336Next